sulindac / Generic mfg. - LARVOL DELTA

Crossed Paths in Liver Injury: Drugs, Herbals, and Genetic Polymorphisms (ACG 2026) - "Two weeks prior, he had been treated with clindamycin and sulindac for a dental infection. Figure: Figure 1: MRI abdomen with contrast demonstrating cirrhotic morphology and a 1.5 cm liver lesion, unchanged from prior imaging. Figure: Figure 2: Pharmacogenomic testing results demonstrating a CYP3A5 poor metabolizer phenotype."

Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Metabolic Disorders • CYP3A5

Single-Cell RNA Sequencing Reveals Immune Dysregulation and Candidate Drug Targets in Endometriosis. (PubMed, Cells) - "Computational drug repurposing analysis prioritized upadacitinib, sorafenib, alpelisib, and sulindac as hypothetical candidates for further investigation, with molecular docking identifying favorable predicted binding affinity scores, particularly for HSP90AA1. These results reinforce a systemic, immune-mediated view of endometriosis and nominate HSP90AA1 and PLCG2 as novel candidate targets that now require biochemical, chemical, and in vivo validation."

Journal • Endometriosis • Gynecology • Infertility • Inflammation • Pain • Sexual Disorders • Women's Health • CDC37 • HSP90AA1 • PLCG2

Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. (PubMed, Gut) - P2 | "In this single-arm, multi-centre trial of participants with FAP, erlotinib one time per week resulted in markedly lower duodenal polyp burden, and modestly reduced lower GI polyp burden, after 6 months of intervention. While AEs were still reported by nearly three-quarters of all participants, these events were generally lower grade and well-tolerated. These findings support further investigation of erlotinib as an effective, acceptable cancer preventive agent for FAP-associated GI polyposis."

Journal • P2 data • Gastrointestinal Disorder • Genetic Disorders • Oncology

Formal allylic C(sp3)−H carboxylation with CO2 via copper metallaphotoredox catalysis (ACS-Fall 2026) - "This strategy lies in combining highly reducing photocatalysts to generate alkene radical anion intermediates with copper catalysis to orchestrate regioselective elimination, providing a distinct pathway from traditional allylic C(sp3)–H functionalization via forming allyl-metal intermediates. This method features high atom and step economy, broad substrate scope, good functional group tolerance, facile scalability, and easy access to valuable compounds, including diverse bioactive molecules, natural products, and 13C-labeled anti-inflammatory drug sulindac."

Enhanced drug-disease association prediction through representation learning on similarity networks. (PubMed, Biol Methods Protoc) - "After rigorous evidence filtering, 12 predicted drug-disease associations showed plausible clinical support, including Sulindac-Breast Neoplasms, Methotrexate-Schizophrenia, and Liothyronine-Breast Neoplasms. Overall, these findings demonstrate that SimNetRLDR provides an effective, robust, and biologically meaningful framework for computational drug repositioning."

Journal • Breast Cancer • CNS Disorders • Oncology • Psychiatry • Schizophrenia • Solid Tumor

An unresectable desmoid tumour demonstrating long-term complete response to imatinib monotherapy: a case report. (PubMed, J Med Case Rep) - "We describe a case of complete and durable remission achieved with imatinib monotherapy in an unresectable mesenteric desmoid tumour with the patient remaining disease-free at 10 years. This case highlights the potential for long-term complete response and underscores the need for prospective data to guide treatment duration and cessation criteria."

Journal • Monotherapy • Desmoid Tumors • Oncology • Sarcoma • Solid Tumor • KIT • PDGFRA

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Real-world efficacy of nirogacestat compared to prior standard-of-care (SOC) systemic agents in desmoid tumors. (ASCO 2026) - "Nirogacestat showed a higher tumor response rate than other systemic therapies(sorafenib, pazopanib, or tamoxifen/sulindac) in this real-world analysis. However, no significant PFS improvement was observed, likely due to the small sample size and shorter follow-up for the nirogacestat group. These findings support the activity of nirogacestat in desmoid tumors and warrant validation in larger, long-term studies."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Desmoid Tumors • Oncology • Sarcoma

Integrating machine learning and spatiotemporal transcriptomics to build a diagnostic model for osteosarcoma metastasis and to decipher the role of necroptosis genes. (PubMed, Discov Oncol) - "This study provides a diagnostic model for osteosarcoma metastasis and proposes that MYC/TNFRSF21 drive metastasis via a "necroptosis‑immune exemption" axis, suggesting new therapeutic strategies."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • MYC • TNFRSF21

Anticancer activity of fluoxetine Janus dendrimer against cancer cells. (PubMed, Artif Cells Nanomed Biotechnol) - "Significant inhibition of the growth of cancer cells was observed for the Janus dendrimers with sulindac-celecoxib, which was selective against MCF-7; and Janus dendrimers with fluoxetine were highly cytotoxic. The fluoxetine-dendrimer could be a candidate for the development of new pharmacological strategies for the treatment and prevention of MCF-7 cancer."

Journal • Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Mechanistic Insight into Formation and Release Enhancement of Sulindac-Amino Acid Small-Molecule Hydrogels. (PubMed, Pharm Res) - "This study presents a viable formulation approach for overcoming the poor water solubility of insoluble drugs through the design of small-molecule hydrogel formulations."

Journal

Novel NSAID Analogs Exhibit Anti-Leukemic Activity Through Modulation of Apoptotic and Survival Pathways. (PubMed, Int J Mol Sci) - "NSI-5 exerted the highest anti-leukemic activity among these sulindac analogs, as determined at a sub-micromolar level in all cell lines studied, by IC50...Collectively, these findings indicate that NSI-5 is a promising in vitro anti-leukemic lead compound, with activity associated with mitochondrial dysfunction and altered redox regulation. The observed effects are consistent with previously reported COX-independent activity of structurally related NSAID derivatives, and support further investigation of NSI-5 in preclinical models."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • BAK1 • BAX • BCL2 • CASP3 • CAT

Identification of biomarkers related to amino acid metabolism in nonobstructive azoospermia by bioinformatics. (PubMed, Medicine (Baltimore)) - "Remarkably, sodium selenite, aflodac, and genistein were commonly predicted by the biomarkers...Ultimately, AKT1 and SHC1 were significantly upregulated in NOA. This study identified 3 biomarkers as being associated with NOA, providing valuable clues to help treat and predict NOA."

Biomarker • Journal • Hepatology • Infertility • Liver Failure • Lung Cancer • Oncology • Sexual Disorders • Solid Tumor • AKT1

Combination of a pesco vegetarian diet with non-steroidal anti-inflammatory drugs reduces colorectal cancer risk and modulates gut microbiota in PIRC rats. (PubMed, Sci Rep) - "This study investigated the synergic chemopreventive potential of two non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid (ASA) and sulindac (SU), in combination with a pesco-vegetarian diet (PVD), using Apc-mutated PIRC rats, a well-established model of CRC. Notably, taxa such as Roseburia and Colidextribacter, previously linked to intestinal homeostasis and anti-inflammatory activity, were modulated by ASA and diet, suggesting a microbiome-mediated chemoprevention although mechanistic effect still need to be understood. These findings underscore the independent and complementary roles of diet and pharmacological interventions in CRC prevention and highlight the gut microbiota as a promising target for future personalised preventive strategies."

Journal • Preclinical • Colorectal Cancer • Genetic Disorders • Oncology • Solid Tumor • APC

Formal Allylic C(sp3)-H Carboxylation With CO2 via Copper Metallaphotoredox Catalysis. (PubMed, Angew Chem Int Ed Engl) - "This strategy lies in combining highly reducing photocatalysts to generate alkene radical anion intermediates with copper catalysis to orchestrate regioselective elimination, providing a distinct pathway from traditional allylic C(sp3)─H functionalization via forming allyl-metal intermediates. This method features high atom and step economy, broad substrate scope, good functional group tolerance, facile scalability, and easy access to valuable compounds, including diverse bioactive molecules, natural products, and 13C-labeled anti-inflammatory drug sulindac."

Journal

Formation and Release Enhancement of a Novel Small-Molecule Hydrogel Containing Sulindac and Meglumine. (PubMed, Gels) - "These enhanced performances were attributed to the high-energy state of the hydrogel itself and the molecular complexation between SUL and MEG. In conclusion, this study presents a feasible formulation strategy for overcoming the poor water solubility of insoluble drugs through the development of small-molecule hydrogel formulations."

Journal

Machine learning-based QSAR and molecular modeling of phytocompounds in Barleria buxifolia L. as a potential aldose reductase inhibitor. (PubMed, Front Bioinform) - "By redocking the co-crystallised ligand sulindac sulfone into the aldose reductase binding site, the researchers proved the docking approach's reliability with a 0.117 Å root mean square deviation (RMSD)...Further verifying its potency, an AI-assisted PCA-PLS QSAR model also showed high predictive performance (R2 = 0.692), with 9CDOT showing a projected pIC50 of 7.52 (IC50 = 30 nM). To determine its therapeutic efficacy and investigate its potential as a lead candidate for the management of diabetes complications, more experimental validation is required."

Journal • Diabetes • Metabolic Disorders • AKR1B1

Nonsteroidal Anti-Inflammatory Drug Use in Orthopaedic Surgery Practice is Increasing: A Review of Medicare Part D Claims from 2013 to 2021 (AAOS 2026) - "The use of ketorolac, meloxicam, diclofenac, celecoxib, and ibuprofen significantly increased with time while the use of naproxen, nabumetone, etodolac, sulindac, piroxicam, and indomethacin significantly decreased (Table 2). Outpatient NSAID prescriptions by orthopaedic surgery providers increased between 2013 and 2021and is likely underestimated by these data as the majority of NSAIDs are available as over the counter medications. Further study is needed to identify if these practice patterns represent rising use in the setting of fracture surgery as historically this has been the subspecialty where their use was most limited."

Medicare • Reimbursement • Review • Surgery • US reimbursement • Musculoskeletal Diseases • Orthopedics

Electrochemical Oxidation-Induced Difunctionalization of the Sulindac Alkene Moiety with Diselenides. (PubMed, J Org Chem) - "This methodology delivers diverse sulindac derivatives in moderate to excellent yields (up to 92%) with a broad functional group tolerance. Mechanistic studies reveal a radical-radical cross-coupling process, offering a novel strategy for alkene difunctionalization."

Journal

A Validated LC-MS/MS Method for the Determination of Sulindac and Its Metabolite Su-EP‑C in Human Plasma and Their Pharmacokinetic Application in Healthy Volunteers. (PubMed, ACS Omega) - "The plasma matrix, at both -20 °C and -70 °C, remained stable for 52 days with 5 freeze-thaw cycles. The method was successfully applied to fasting and postprandial pharmacokinetic clinical trials of orally administered sulindac tablets."

Journal • PK/PD data

Sulindac as a precision microRNA modulator in early-stage K-Ras-driven oncogenesis. (PubMed, Cell Death Discov) - No abstract available

Journal • Oncology • KRAS

Pharmacological reversal of LPS-induced cognitive impairments: evidence for inflammation-dependent and independent mechanisms (Neuroscience 2025) - "Fifteen compounds proved effective in reversing cognitive deficits and were categorized as follows: i) Anti-inflammatory NSAIDs & Steroids: Ibuprofen, indomethacin, sulindac, dexamethasone...iii) Synaptic & Neurotransmitter Modulators: Memantine, donepezil, GRN 529. iv) Metabolic & Signaling Agents: Metformin, semaglutide, neflamapimod. Two interventions—nilotinib and methylene blue—were ineffective...The convergence of benefits across anti-inflammation, oxidative stress reduction, synaptic modulation, and metabolic regulation underscores the multifactorial nature of inflammation-driven neurodegeneration. Identifying both effective and ineffective agents highlights the model's translational potential and discriminative validity."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Sulindac sulfide suppresses oncogenic transformation through let-7b-mediated repression of K-Ras signaling. (PubMed, Cell Death Discov) - No abstract available

Journal • Oncology • KRAS • MIRLET7B

Unexpected effects of antibiotics on microbiota-mediated drug metabolism in a fistulated dog model. (PubMed, Eur J Pharm Sci) - "We investigated the metabolism of metronidazole and sulindac, two structurally and pharmacologically distinct drugs, before and after broad-spectrum antibiotic treatment...These findings underscore the complexity of microbiota-host-drug interactions and provide important insights for the development of translational microbiome-pharmacology models. Additionally, the drawbacks over the use of antibiotic-treated animal models to study microbiota-drug interactions are discussed due to antibiotic-induced changes in intestinal permeability and efflux that may influence drug absorption and metabolism."

Journal

Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection. (PubMed, Viruses) - "Overall, our studies demonstrated that DFMO and Sulindac administration as the prophylaxis regimen provided strong protection against the lethal outcome of SARS-CoV-2 infection and that male mice benefited more from the polyamine-targeted antiviral treatment than female mice. Our findings underscore the importance of evaluation of the antiviral activity of the drugs in the context of sex and age."

Journal • Preclinical • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Solid Tumor